Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.

Eosinophils play an important role in the pathogenesis of asthma. Several pro-inflammatory responses of eosinophils are primed in vivo in this disease. The aim of the present study was to investigate whether regular antiasthma treatment could modulate priming-sensitive cytotoxic mechanisms of human eosinophils. In a randomized, two-centre, double-blind parallel group study, the effect of 8 weeks of treatment with salmeterol xinafoate 50 microg b.i.d., beclomethasone dipropionate 400 microg b.i.d. or both on pulmonary function and the activation of priming-sensitive cytotoxic mechanisms of eosinophils, i.e. degranulation of eosinophil cationic protein (ECP) in serum, and activation of isolated eosinophils in the context of induction of the respiratory burst and release of platelet-activating factor (PAF) were tested. These effects were evaluated in 40 allergic asthmatics before and 24 h after allergen inhalation challenge. Whereas baseline forced expiratory volume in one second (FEV1) improved in all treatment groups, only treatment with a combination of salmeterol and beclomethasone significantly inhibited the allergen-induced increase in serum ECP, and (primed/unprimed) PAF-release, suggesting inhibition of eosinophil priming after allergen challenge. In contrast to the combination therapy, monotherapy with beclomethasone had no influence on allergen-induced PAF-release, suggesting an additional anti-inflammatory effect of salmeterol during combination therapy. Monotherapy with beclomethasone inhibited the prechallenge serum-treated zymosan (STZ) (0.1 mg mL(-1))-induced respiratory burst and the allergen-induced increase in serum ECP levels, reflecting pre- and postchallenge anti-inflammatory effects. During monotherapy with salmeterol, an allergen-induced increase in serum ECP concentration and STZ (0.1 mg x mL(-1))-induced respiratory burst was observed, suggesting that treatment with salmeterol alone had no effect on priming-sensitive eosinophil cytotoxic mechanisms. In conclusion, this study shows that standard asthma therapy leads to inhibition of eosinophil priming of cytotoxic mechanisms in vivo.

[1]  D. Cockcroft,et al.  Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.

[2]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[3]  E. Knol,et al.  The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. , 1996, The European respiratory journal. Supplement.

[4]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[5]  F. Hargreave,et al.  Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. , 1996, The European respiratory journal.

[6]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[7]  R. Dahl,et al.  The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X , 1993, Allergy.

[8]  P. Venge.  Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  L. Koenderman,et al.  Upregulation of formyl-peptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma. , 1993, The Journal of allergy and clinical immunology.

[10]  J. Lammers,et al.  Cytokine priming of the respiratory burst in human eosinophils is Ca2+ independent and accompanied by induction of tyrosine kinase activity , 1993, Journal of leukocyte biology.

[11]  S. Anderson,et al.  Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .

[12]  W. Busse.  Mechanisms of inflammation and their therapeutic implications in the asthmatic patient. , 1992, Annals of allergy.

[13]  A. Wardlaw,et al.  IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. , 1992, Journal of immunology.

[14]  M. Johnson,et al.  Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung , 1991, British journal of pharmacology.

[15]  S. Holgate,et al.  Protection against allergen-induced asthma by salmeterol , 1990, The Lancet.

[16]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[17]  J. Bousquet,et al.  Comparison between RAST and Pharmacia CAP system: a new automated specific IgE assay. , 1990, The Journal of allergy and clinical immunology.

[18]  G. Kitas,et al.  Purification of human blood eosinophils by negative selection using immunomagnetic beads. , 1989, Journal of immunological methods.

[19]  L. Koenderman,et al.  Increased sensitivity of the chemoattractant-induced chemiluminescence in eosinophils isolated from atopic individuals. , 1989, Immunology.

[20]  W. Busse,et al.  The appearance of hypodense eosinophils in antigen-dependent late phase asthma. , 1989, The American review of respiratory disease.

[21]  L. Koenderman,et al.  An Improved Method for the Isolation of Eosinophilic Granulocytes From Peripheral Blood of Normal Individuals , 1988, Journal of leukocyte biology.

[22]  R. Dahl,et al.  Variations of Blood Eosinophils and Eosinophil Cationic Protein in Serum in Patients with Bronchial Asthma , 1978, Allergy.

[23]  D. Cockcroft,et al.  Allergen‐induced increase in non‐allergic bronchial reactivity , 1977, Clinical allergy.

[24]  F. Hargreave,et al.  Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.

[25]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[26]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[27]  Partridge,et al.  International Consensus Report on Diagnosis and Treatment of Asthma. , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  L. Koenderman,et al.  In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. , 1992, Blood.

[29]  P. Venge,et al.  Degranulation of eosinophils from pollen-atopic patients with asthma is increased during pollen season. , 1992, The Journal of allergy and clinical immunology.

[30]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.